Anastrazole - Hormonal Chemotherapy (Feb 2003)
Drug Name:
Anastrazole - Hormonal Chemotherapy (Feb 2003)
List Of Brands:
Indication Type Description:
Pharmacology/ Pharmacokinetics
Drug Interaction:
Anastrozole is a weak inhibitor of cytochrome P450 in vitro and not expected to have clinically significant interactions with drugs metabolised by cytochrome P450.
Estrogen use with anastrozole - use other options for conditions in which estrogen is indicated, if estrogen is used.
Indication:
Advanced breast cancer in potmenopausal women
New drugs approved For Marketing by Drug Controller General of India(DCGI )
during the period January 1988 to November 2014
(Ref- IDMA Annual Publication 2015)
Name of Drug Indication Date of Approval
Anastrazole Anti-cancer 10-02-2003
Adverse Reaction:
Hot flushes, Vaginal dryness, vaginal bleeding,
Hair thinning, Amorexia, Nausea, vomiting, Diarrhoea,
Headache, Arthlagia,
Bone fractures,
Rash (including Stevens Johnson syndrome)
Asthenia and drowsiness may intially affect ability to drive or operate machinery.
Contra-Indications:
Pregnancy and lactation,
moderate or severe hepatic disease/renal impairment ,
premenstrual women.
Special Precautions
Estrogen containing therapies should not be used with anastrozole as they may diminish its pharmacologic action.
Tamoxifen should not be co-administered with anastrazole.
Dosages/ Overdosage Etc:
Indication-
Advanced breast cancer in potmenopausal women
Dosage-
For early disease 1mg daily, recommended duration of therapy is 5 years.
Patient Information:
Refer Precautions and contraindcations
Pharmacology/ Pharmacokinetics:
Pharmacology
Anastrazole is a reversible (Type II) nonsteroidal anomatase inhibitor. Aramatase belongs to the group of cyclochrome P-450 enzymes and catalyses the final and rate-limiting step in conversion of androgens to estrogens in peripheral tissues.
Pharmacokinetics
After oral adminostration,anastrazole is rapidly and completely absorbed from the gastrointestinal tract.
Food slightly decreases its rate of absorption.
Minimum plasma levels are reached approximately 2 hours after dosing.
Steady state concentration is reached after 9-10 days o once daily administration and it is 3-4 fold higher than after single dose administration.
The estimated half-life of Anastrazole is approximately 40- 50 hrs,
Interaction with Food:
Food slightly decreases its rate of absorption.
Pregnancy and lactation:
Use contra-indicated in pregnancy and lactation.